← back to search

Amber Salter

Southwestern Medical Center · US
Area of research
Pathology and Forensic Medicine · Neurology
Research interest
Research interests include Multiple Sclerosis Research Studies, Amyotrophic Lateral Sclerosis Research, Peripheral Neuropathies and Disorders, and Systemic Sclerosis and Related Diseases.
h-index
46
citations
8,491
works
352
NIH funding
primary concept
email

Recent publications

Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria
The Lancet Neurology 2025cited by 254position: middledoi
Advancing multiple sclerosis management in older adults
Nature Reviews Neurology 2025cited by 19position: middledoi
Cognitive Impairment and Dementia-Related Diagnoses in Chronic Traumatic Encephalopathy
Neurology 2025cited by 4position: middledoi
Infection, Relapses, and Pseudo-Relapses in Individuals With Multiple Sclerosis
Neurology Clinical Practice 2025cited by 2position: firstdoi
Body mass index and sleep disorders after moderate-to-severe traumatic brain injury – a national TBI model systems study
Brain Injury 2025cited by 1position: middledoi
Comorbidity and Disease Activity in Multiple Sclerosis
JAMA Neurology 2024cited by 38position: firstdoi
Investigating the Prevalence of Comorbidity in Multiple Sclerosis Clinical Trial Populations
Neurology 2024cited by 24position: firstdoi
Randomised controlled trial of intermittent calorie restriction in people with multiple sclerosis
Journal of Neurology Neurosurgery & Psychiatry 2024cited by 16position: middledoi
Priority setting: women’s health topics in multiple sclerosis
Frontiers in Neurology 2024cited by 14position: middledoi
Cognitive rehabilitation effects on grey matter volume and Go-NoGo activity in progressive multiple sclerosis: results from the CogEx trial
Journal of Neurology Neurosurgery & Psychiatry 2024cited by 9position: middledoi
Focusing on neural mechanisms of exercise training benefits in multiple sclerosis
Multiple Sclerosis and Related Disorders 2024cited by 8position: lastdoi
Utility of Progression Independent of Relapse Activity as a Trial Outcome in Relapsing-Remitting Multiple Sclerosis
Neurology 2024cited by 7position: middledoi
Disease-modifying therapy initiation patterns in multiple sclerosis in three large MS populations
Therapeutic Advances in Neurological Disorders 2024cited by 6position: lastdoi
Association of patient-reported cognitive impairment with quality of life and employment in multiple sclerosis
Multiple Sclerosis and Related Disorders 2024cited by 5position: lastdoi
Etiology, effects and management of comorbidities in multiple sclerosis: recent advances
Frontiers in Immunology 2023cited by 100position: middledoi
Cognitive rehabilitation and aerobic exercise for cognitive impairment in people with progressive multiple sclerosis (CogEx): a randomised, blinded, sham-controlled trial
The Lancet Neurology 2023cited by 60position: middledoi
Improving the efficiency of clinical trials in multiple sclerosis
Multiple Sclerosis Journal 2023cited by 17position: middledoi
Introducing a core dataset for real-world data in multiple sclerosis registries and cohorts: Recommendations from a global task force
Multiple Sclerosis Journal 2023cited by 11position: middledoi
Multiple sclerosis progression: time for a new mechanism-driven framework
The Lancet Neurology 2022cited by 587position: middledoi
Alterations of host-gut microbiome interactions in multiple sclerosis
EBioMedicine 2022cited by 139position: middledoi
Physical and Mental Health–Related Quality of Life Trajectories Among People With Multiple Sclerosis
Neurology 2022cited by 24position: middledoi
Structural and functional magnetic resonance imaging correlates of fatigue and dual-task performance in progressive multiple sclerosis
Journal of Neurology 2022cited by 15position: middledoi
Disparities in Telehealth Care in Multiple Sclerosis
Neurology Clinical Practice 2022cited by 14position: lastdoi
Physical activity as a correlate of symptoms, quality of life, comorbidity, and disability status in Hispanics with multiple sclerosis
Disability and health journal 2022cited by 9position: lastdoi
Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β
Multiple Sclerosis and Related Disorders 2022cited by 7position: middledoi
2233 Updated results of the COVID-19 in MS global data sharing initiative: anti-CD20 DMTs deleterious for COVID-19 severity but interferons not protective among people with MS
Abstracts 2022cited by 0position: middledoi
Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis
JAMA Neurology 2021cited by 281position: firstdoi
Alterations of the gut mycobiome in patients with MS
EBioMedicine 2021cited by 72position: middledoi
Diagnostic Performance of LI-RADS Version 2018 for Evaluation of Pediatric Hepatocellular Carcinoma
Radiology 2021cited by 30position: middledoi
Associations of DMT therapies with COVID-19 severity in multiple sclerosis
medRxiv 2021cited by 28position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Gary Cutter · Epilepsy Foundation47 papers (2012–2025)Robert J. Fox · Cleveland Clinic25 papers (2013–2025)Stacey S. Cofield · University of Alabama at Birmingham11 papers (2013–2018)Kathryn C. Fitzgerald · Southwestern Medical Center8 papers (2017–2024)Maria Pia Amato · University of Alabama at Birmingham6 papers (2020–2024)Peter Feys · KU Leuven6 papers (2020–2024)Brian M. Sandroff · University of Alabama at Birmingham6 papers (2020–2024)Jeremy Chataway · Queen Mary University of London6 papers (2020–2024)Robert W. Motl · University of Illinois Urbana-Champaign5 papers (2020–2024) · 5 papers (2019–2024)Samantha Lancia · Southwestern Medical Center5 papers (2022–2025)John DeLuca · Rutgers, The State University of New Jersey5 papers (2020–2024)Matilde Inglese · University of Genoa5 papers (2020–2024)Ulrik Dalgas · Aarhus University5 papers (2020–2024)Maria A. Rocca · Vita-Salute San Raffaele University5 papers (2020–2024)Jennifer Freeman · University of Sheffield5 papers (2020–2024)Rod Middleton · Swansea University5 papers (2019–2024)Massimo Filippi · McGill University Health Centre5 papers (2020–2024)Anthony Feinstein · St. Michael's Hospital5 papers (2020–2024) · 5 papers (2020–2024)